Table 1 Epidemiological and clinical data of the case study.
| HBsAG− | HBsAG+ | |||
|---|---|---|---|---|
| Anti‐HBc+ | Anti‐HBc+ | Anti‐HBc− | ||
| Anti‐HBs+ | ||||
| Number | 18 | 3 | 31 | 6 |
| Age (years) (range) | 58 (51 to 70) | 52 (46 to 73) | 44 (28 to 71) | 53 (47 to 70) |
| Sex (M/F) | 8/10 | 2/1 | 11/20 | 4/2 |
| HCV | 8 | – | 7 | – |
| Lymphoma grading low/intermediate/high | 8/6/4 | 0/2/1 | 10/11/10 | 3/1/1/1 maltoma |
| Previous treatment with lamivudine | – | – | – | 6 |
HCV, hepatitis C virus.